Skip to main content

Research Repository

Advanced Search

All Outputs (59)

Alteration in endothelial permeability occurs in response to the activation of PAR2 by factor Xa but not directly by the TF-factor VIIa complex (2019)
Journal Article
Benelhaj, N. E., Maraveyas, A., Featherby, S., Collier, M. E., Johnson, M. J., & Ettelaie, C. (2019). Alteration in endothelial permeability occurs in response to the activation of PAR2 by factor Xa but not directly by the TF-factor VIIa complex. Thrombosis Research, 175, 13-20. https://doi.org/10.1016/j.thromres.2019.01.009

Alterations in the endothelial permeability occur in response to the activation of coagulation mechanisms in order to control clot formation. The activation of the protease activated receptors (PAR) can induce signals that regulate such cellular resp... Read More about Alteration in endothelial permeability occurs in response to the activation of PAR2 by factor Xa but not directly by the TF-factor VIIa complex.

Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial (2018)
Journal Article
Hutchinson, A., Rees, S., Young, A., Maraveyas, A., Date, K., & Johnson, M. J. (2019). Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial. Palliative medicine, 33(5), 510-517. https://doi.org/10.1177/0269216318815377

Background: Cancer patients have a four- to fivefold greater risk of thrombosis than the general population. Recommended treatment for cancer-associated thrombosis is 3–6 months of low-molecular-weight heparin. The ‘select-d’ trial is an open-label,... Read More about Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial.

CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study (2018)
Journal Article
Jackson, G., Gabe, R., Johnson, M., Date, K., Harman, D., Maraveyas, A., …Lind, M. J. (2019). CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study. Journal of Geriatric Oncology, 10(1), 175-177. https://doi.org/10.1016/j.jgo.2018.07.005

One of the primary risk factors in the development of cancer is older age. The demographic shift to an ageing population has given rise to an increased number of older patients with cancer. The extreme heterogeneity within this population renders app... Read More about CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study.

Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D) (2018)
Journal Article
Young, A. M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., …Levine, M. (2018). Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). Journal of Clinical Oncology, 36(20), 2017-2023. https://doi.org/10.1200/JCO.2018.78.8034

© 2018 by American Society of Clinical Oncology. Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this stud... Read More about Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D).

Cancer patients’ experiences of living with venous thromboembolism: A systematic review and qualitative thematic synthesis (2018)
Journal Article
Benelhaj, N. B., Hutchinson, A., Maraveyas, A. M., Seymour, J. D., Ilyas, M. W., & Johnson, M. J. (2018). Cancer patients’ experiences of living with venous thromboembolism: A systematic review and qualitative thematic synthesis. Palliative medicine, 32(5), 1010-1020. https://doi.org/10.1177/0269216318757133

Background: Cancer-Associated thrombosis is common. Recommended treatment is daily injected low-molecular-weight heparin for 6months. Most studies focus on prophylaxis and treatment; few have explored patients’ experience. Aims To identify and sy... Read More about Cancer patients’ experiences of living with venous thromboembolism: A systematic review and qualitative thematic synthesis.

Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography (2017)
Journal Article
Adesanya, M. A., Maraveyas, A., & Madden, L. (2017). Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography. Blood Coagulation and Fibrinolysis, 28(8), 602-611. https://doi.org/10.1097/mbc.0000000000000644

© 2017 Wolters Kluwer Health, Inc. All rights reserved. Calibrated automated thrombography (CAT) is emerging as a reliable tool for real-Time estimation of thrombin generation potential. There is a clinical need for knowledge about the pathways under... Read More about Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography.

Investigation of the filamin A-Dependent mechanisms of tissue factor incorporation into microvesicles (2017)
Journal Article
Collier, M. E. W., Ettelaie, C., Goult, B. T., Maraveyas, A., & Goodall, A. H. (2017). Investigation of the filamin A-Dependent mechanisms of tissue factor incorporation into microvesicles. Thrombosis and haemostasis, 117(11), 2034-2044. https://doi.org/10.1160/TH17-01-0009

We have previously shown that phosphorylation of tissue factor (TF) at Ser253 increases the incorporation of TF into microvesicles (MVs) following protease-activated receptor 2 (PAR2) activation through a process involving filamin-A, whereas Ser258 p... Read More about Investigation of the filamin A-Dependent mechanisms of tissue factor incorporation into microvesicles.

Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer (2017)
Journal Article
Date, K., Ettelaie, C., & Maraveyas, A. (2017). Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer. Journal of thrombosis and haemostasis : JTH, 15(12), 2289-2299. https://doi.org/10.1111/jth.13871

© 2017 International Society on Thrombosis and Haemostasis Summary: Cancer is associated with an increased risk of venous thromboembolism (VTE); the exact mechanisms for the induction of VTE remain to be fully elucidated, but it is widely acknowledge... Read More about Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer.

Peptidyl-prolyl isomerase 1 (Pin1) preserves the phosphorylation state of tissue factor and prolongs its release within microvesicles (2017)
Journal Article
Ettelaie, C., Collier, M., Featherby, S., Greenman, J., & Maraveyas, A. (2018). Peptidyl-prolyl isomerase 1 (Pin1) preserves the phosphorylation state of tissue factor and prolongs its release within microvesicles. BBA - Molecular Cell Research, 1865(1), 12-24. https://doi.org/10.1016/j.bbamcr.2017.09.016

© 2017 Elsevier B.V. The exposure and release of TF is regulated by post-translational modifications of its cytoplasmic domain. Here, the potential of Pin1 to interact with the cytoplasmic domain of TF, and the outcome on TF function was examined. MD... Read More about Peptidyl-prolyl isomerase 1 (Pin1) preserves the phosphorylation state of tissue factor and prolongs its release within microvesicles.

Cancer microvesicles induce tissue factor-related procoagulant activity in endothelial cells in vitro (2017)
Journal Article
Adesanya, M. A., Maraveyas, A., & Madden, L. A. (2017). Cancer microvesicles induce tissue factor-related procoagulant activity in endothelial cells in vitro. Blood Coagulation and Fibrinolysis, 28(5), 365-372. https://doi.org/10.1097/MBC.0000000000000607

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. Microvesicles associated with tissue factor (TF) may play a role in cancer-related venous thromboembolism; however, not much is known about their interaction with the tumour stroma, es... Read More about Cancer microvesicles induce tissue factor-related procoagulant activity in endothelial cells in vitro.

Characterisation of duramycin as an anti-cancer agent (2016)
Thesis
Broughton, L. J. (2016). Characterisation of duramycin as an anti-cancer agent. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4219417

Duramycin is a relatively small (~2kDa) tetracyclic peptide that has a defined three-dimensional (3D) structure, this structure forms a stable binding pocket which specifically recognises the plasma membrane phospholipid phosphatidylethanolamine (PE)... Read More about Characterisation of duramycin as an anti-cancer agent.

Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy (2016)
Journal Article
Broughton, L. J., Giuntini, F., Savoie, H., Bryden, F., Boyle, R. W., Maraveyas, A., & Madden, L. A. (2016). Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy. Journal of photochemistry and photobiology. B, Biology, 163, 374-384. https://doi.org/10.1016/j.jphotobiol.2016.09.001

Duramycin, through binding with phosphatidylethanolamine (PE), has been shown to be a selective molecular probe for the targeting and imaging of cancer cells. Photodynamic therapy aims to bring about specific cytotoxic damage to tumours through deliv... Read More about Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy.

Oligoubiquitination of tissue factor on Lys255 promotes Ser253-dephosphorylation and terminates TF release (2016)
Journal Article
Ettelaie, C., Collier, M. E., Featherby, S., Greenman, J., & Maraveyas, A. (2016). Oligoubiquitination of tissue factor on Lys255 promotes Ser253-dephosphorylation and terminates TF release. BBA - Molecular Cell Research, 1863(11), 2846-2857. https://doi.org/10.1016/j.bbamcr.2016.09.005

Restriction of tissue factor (TF) activity at the cell surface and TF release are critical for prevention of excessive coagulation. This study examined the regulation of TF dephosphorylation and its release through ubiquitination. A plasmid containin... Read More about Oligoubiquitination of tissue factor on Lys255 promotes Ser253-dephosphorylation and terminates TF release.

Duramycin-induced calcium release in cancer cells (2016)
Journal Article
Broughton, L. J., Crow, C., Madden, L. A., & Maraveyas, A. (2016). Duramycin-induced calcium release in cancer cells. Anti-cancer drugs, 27(3), 173-182. https://doi.org/10.1097/cad.0000000000000313

Introduction: Duramycin through binding with phosphatidylethanolamine (PE) has shown potential to be an effective anti-tumour agent. However its mode of action in relation to tumour cells is not fully understood. Methods: PE expression on the surface... Read More about Duramycin-induced calcium release in cancer cells.

Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression (2016)
Journal Article
Ettelaie, C., Collier, M. E. W., Featherby, S., Benelhaj, N. E., Greenman, J., & Maraveyas, A. (2016). Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression. Thrombosis journal, 14(2), Article ARTN 2. https://doi.org/10.1186/s12959-016-0075-3

Background Despite the association of cancer-derived circulating tissue factor (TF)-containing microvesicles and hypercoagulable state, correlations with the incidence of thrombosis remain unclear. Methods In this study the upregulation of TF re... Read More about Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression.

Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients (2016)
Journal Article
Van der Hulle, T., den Exter, P. L., Planquette, B., Meyer, G., Soler, S., Monreal, M., …Klok, F. A. (2016). Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. Journal of thrombosis and haemostasis : JTH, 14(1), 105-113. https://doi.org/10.1111/jth.13172

Essentials: We performed a pooled analysis of 926 patients with cancer-associated incidental pulmonary embolism (IPE). Vitamin K antagonists (VKA) are associated with a higher risk of major hemorrhage. Recurrence risk is comparable after subsegmental... Read More about Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients.

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial (2015)
Journal Article
Valle, J. W., Wasan, H., Lopes, A., Backen, A. C., Palmer, D. H., Morris, K., …Bridgewater, J. A. (2015). Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. The lancet oncology, 16(8), 967-978. https://doi.org/10.1016/S1470-2045%2815%2900139-4

© 2015 Valle et al. Open Access article distributed under the terms of CC BY. Background: Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of VEGF and its receptors... Read More about Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.

Accumulation of tissue factor in endothelial cells induces cell apoptosis, mediated through p38 and p53 activation (2015)
Journal Article
ElKeeb, A. M., Collier, M. E. W., Maraveyas, A., & Ettelaie, C. (2015). Accumulation of tissue factor in endothelial cells induces cell apoptosis, mediated through p38 and p53 activation. Thrombosis and haemostasis, 114(2), 364-378. https://doi.org/10.1160/th14-09-0795

We previously reported that high levels of tissue factor (TF) can induce cellular apoptosis in endothelial. In this study, TF-mediated mechanisms of induction of apoptosis were explored. Endothelial cells were transfected to express wild-type TF. Add... Read More about Accumulation of tissue factor in endothelial cells induces cell apoptosis, mediated through p38 and p53 activation.

Study of the thrombogenicity induced by the cytotoxic treatment of malignant disease (2014)
Thesis
Hall, J. (2014). Study of the thrombogenicity induced by the cytotoxic treatment of malignant disease. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4216550

Cancer and its treatment are frequently complicated by the development of venous thromboembolism (VTE). Interestingly, VTE incidence rates vary according to tumour type and the chemotherapy regimen administered. Yet, the precise mechanisms responsibl... Read More about Study of the thrombogenicity induced by the cytotoxic treatment of malignant disease.